Document is current
Any future updates will be listed below
-
Authors
Boger, Ron S. https://orcid.org/0000-0002-4467-271X
Chithrananda, Seyone https://orcid.org/0000-0002-3671-9135
Angelopoulos, Anastasios N. https://orcid.org/0000-0001-9787-0579
Yoon, Peter H.
Jordan, Michael I. https://orcid.org/0000-0001-8935-817X
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (D-001)
- License Information
-
More Information
Article History
Received: 12 July 2024
Accepted: 20 December 2024
First Online: 2 January 2025
Change Date: 10 April 2026
Change Type: Update
Change Details: In this article the grant numbers relating to NIH/NIAID given for Jennifer A. Doudna were incorrectly given as “U19AI171110, U54AI170792, U19AI135990, UH3AI150552 and U01AI142817” and should have been “U54AI170792, U19AI135990, UH3AI150552 and U01AI142817”. The original article has been corrected.
Competing interests
: J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Mammoth Biosciences and Scribe Therapeutics, and a director of Altos, Johnson & Johnson and Tempus. J.A.D. is a scientific advisor to Caribou Biosciences, Intellia Therapeutics, Mammoth Biosciences, Inari, Scribe Therapeutics, Felix Biosciences and Algen. J.A.D. also serves as Chief Science Advisor to Sixth Street and a Scientific Advisory Board member at The Column Group. J.A.D. conducts academic research projects sponsored by Roche and Apple Tree Partners. The remaining authors declare no competing interests.
